Midpregnancy prediction of pre-eclampsia using serum biomarkers sFlt-1 and PlGF
Author(s)
Black, Carin
Al-Amin, Ahmed
Stolarek, Caroline
Kane, Stefan C
Rolnik, Daniel Lorber
White, Adrienne
Costa, Fabricio da Silva
Brennecke, Shaun
Griffith University Author(s)
Year published
2019
Metadata
Show full item recordAbstract
Objectives: Pre-eclampsia remains a significant cause of morbidity and mortality. Placental biomarkers soluble Fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) have been investigated previously for their ability to predict pre-eclampsia. We compared the performance of these biomarkers for midpregnancy pre-eclampsia prediction using three different immunoassay platforms. Study design: Prospective study including singleton pregnancies 19–22 weeks’ gestation. Maternal bloods were collected at recruitment. Screening performances using receiver operating characteristic (ROC) curves for PlGF and sFlt-1/PlGF ...
View more >Objectives: Pre-eclampsia remains a significant cause of morbidity and mortality. Placental biomarkers soluble Fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) have been investigated previously for their ability to predict pre-eclampsia. We compared the performance of these biomarkers for midpregnancy pre-eclampsia prediction using three different immunoassay platforms. Study design: Prospective study including singleton pregnancies 19–22 weeks’ gestation. Maternal bloods were collected at recruitment. Screening performances using receiver operating characteristic (ROC) curves for PlGF and sFlt-1/PlGF ratio raw data and MoM values in isolation were evaluated for three immunoassay platforms using selected cut-off values. Main outcome measures: Pre-eclampsia was defined as early-onset (<34 weeks’ at delivery) and preterm (<37 weeks’ at delivery). Results: For prediction of preterm pre-eclampsia, PlGF MoM and sFlt-1/PlGF ratio MoM performed similarly, with areas under the curve (AUC), detection rates (DR) and false positive rates (FPR) for PlGF MoM and sFlt-1/PlGF ratio MoM being 0.77–0.79 and 0.71–0.74, 62.5% for both and 9.7–14.9 and 10.7–17.7, respectively. For the prediction of early-onset pre-eclampsia, sFlt-1/PlGF ratio raw data and MoM values performed similarly, with AUC, DR and FPR being 0.92–0.97 and 0.93–0.96, 100% for both, and 4.13–16.9 and 9.4–12.2, respectively. Conclusions: For midpregnancy prediction of preterm pre-eclampsia, PlGF MoM for all three platforms and sFlt-1/PlGF ratio MoM for the two platforms that tested sFlt-1 performed similarly. For midpregnancy prediction of early-onset pre-eclampsia at midpregnancy, sFlt-1/PlGF ratio raw data and MoM values using the early-onset cut-off for the two platforms that tested sFlt-1 gave similar performance from a clinical perspective.
View less >
View more >Objectives: Pre-eclampsia remains a significant cause of morbidity and mortality. Placental biomarkers soluble Fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) have been investigated previously for their ability to predict pre-eclampsia. We compared the performance of these biomarkers for midpregnancy pre-eclampsia prediction using three different immunoassay platforms. Study design: Prospective study including singleton pregnancies 19–22 weeks’ gestation. Maternal bloods were collected at recruitment. Screening performances using receiver operating characteristic (ROC) curves for PlGF and sFlt-1/PlGF ratio raw data and MoM values in isolation were evaluated for three immunoassay platforms using selected cut-off values. Main outcome measures: Pre-eclampsia was defined as early-onset (<34 weeks’ at delivery) and preterm (<37 weeks’ at delivery). Results: For prediction of preterm pre-eclampsia, PlGF MoM and sFlt-1/PlGF ratio MoM performed similarly, with areas under the curve (AUC), detection rates (DR) and false positive rates (FPR) for PlGF MoM and sFlt-1/PlGF ratio MoM being 0.77–0.79 and 0.71–0.74, 62.5% for both and 9.7–14.9 and 10.7–17.7, respectively. For the prediction of early-onset pre-eclampsia, sFlt-1/PlGF ratio raw data and MoM values performed similarly, with AUC, DR and FPR being 0.92–0.97 and 0.93–0.96, 100% for both, and 4.13–16.9 and 9.4–12.2, respectively. Conclusions: For midpregnancy prediction of preterm pre-eclampsia, PlGF MoM for all three platforms and sFlt-1/PlGF ratio MoM for the two platforms that tested sFlt-1 performed similarly. For midpregnancy prediction of early-onset pre-eclampsia at midpregnancy, sFlt-1/PlGF ratio raw data and MoM values using the early-onset cut-off for the two platforms that tested sFlt-1 gave similar performance from a clinical perspective.
View less >
Journal Title
Pregnancy Hypertension
Volume
16
Subject
Paediatrics
Reproductive medicine
Science & Technology
Life Sciences & Biomedicine
Obstetrics & Gynecology
Peripheral Vascular Disease
Cardiovascular System & Cardiology